Literature DB >> 26916669

Low concentration of formononetin stimulates the proliferation of nasopharyngeal carcinoma cell line CNE2 by upregulating bcl-2 and p-ERK1/2 expression.

Yan Hong Guo1, Yong Wang1, Min Xin1.   

Abstract

Context Formononetin is a typical phytoestrogen, which is a bioactive component found in red clover plants. Previous studies have shown that formononetin inhibits the proliferation of several types of cancer cells, including prostate cancer and osteosarcoma. However, how formononetin affects the proliferation of CNE2 is not clear. Objective The objective of this study is to investigate the effects of formononetin on nasopharyngeal carcinoma cells in vitro, along with the underlying mechanism. Materials and methods CNE2 cells were incubated with various concentrations of formononetin (0, 0.1, 0.2, 0.3 and 1 μM) for 48 h. Cell proliferation was measured by [3-(4,5-dimethylthiazol-2-yl)]-2,5-diphenyltetrazolium bromide (MTT) assay, while the rate of apoptosis was measured by flow cytometry. Bcl-2 and bax mRNA expression levels were determined by real time polymerase chain reaction (RT-PCR), while p-ERK1/2 and bcl-2 protein expression levels were quantified by Western blotting. Results Formononetin promoted the proliferation of CNE2 cells at low concentrations (0, 0.05, 0.1, 0.2, 0.5, 1, 2 and 5 μM), OD values increased from 0.27 ± 0.01 to 0.30 ± 0.01, 0.30 ± 0.01,0.36 ± 0.01, 0.35 ± 0.01, 0.34 ± 0.01, 0.34 ± 0.01 and 0.32 ± 0.01, respectively. The percentage of late apoptosis declined from 6.77% ± 0.73% (0 μM group) to 6.2% ± 0.4% (0.1 μM group), 3.83% ± 0.71% (0.3 μM group) and 5.1% ± 0.52% (1M group). The mRNA levels of bax and bcl-2 were down- and upregulated, respectively, by formononetin. Bcl-2 and p-ERK1/2 protein levels were also upregulated. Conclusions Formononetin stimulates CNE2 cell proliferation and has an inhibitory effect on CNE2 cells apoptosis, which is mediated by the activation of the ERK1/2 signaling pathways.

Entities:  

Keywords:  Apoptosis; bax; promote

Year:  2016        PMID: 26916669     DOI: 10.3109/13880209.2015.1129546

Source DB:  PubMed          Journal:  Pharm Biol        ISSN: 1388-0209            Impact factor:   3.503


  3 in total

Review 1.  Formononetin: A Review of Its Anticancer Potentials and Mechanisms.

Authors:  Kai-Ching Tay; Loh Teng-Hern Tan; Chim Kei Chan; Sok Lai Hong; Kok-Gan Chan; Wei Hsum Yap; Priyia Pusparajah; Learn-Han Lee; Bey-Hing Goh
Journal:  Front Pharmacol       Date:  2019-07-26       Impact factor: 5.810

2.  Low concentration of formononetin promotes proliferation of estrogen receptor-positive cells through an ERα-miR-375-PTEN-ERK1/2-bcl-2 pathway.

Authors:  Yan-Hong Guo; Feng-Yan Tang; Yong Wang; Wen-Jun Huang; Jing Tian; Hui-Ling Lu; Min Xin; Jian Chen
Journal:  Oncotarget       Date:  2017-10-19

3.  Formononetin relieves the facilitating effect of lncRNA AFAP1-AS1-miR-195/miR-545 axis on progression and chemo-resistance of triple-negative breast cancer.

Authors:  Jingjing Wu; Wen Xu; Lina Ma; Jiayu Sheng; Meina Ye; Hao Chen; Yuzhu Zhang; Bing Wang; Mingjuan Liao; Tian Meng; Yue Zhou; Hongfeng Chen
Journal:  Aging (Albany NY)       Date:  2021-07-21       Impact factor: 5.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.